All In Biotech

Drug Trial Radar · NCT07798648

A Study of COVID-19 Vaccine(s) in Children and Adults

A PHASE 3 CLINICAL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162B2 RNA-BASED, VARIANT-ADAPTED VACCINE CANDIDATE(S) AGAINST SARS-COV-2 IN CHILDREN AND ADULTS

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 713 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

713

Actual

Start

Aug 31, 2026

Primary completion

Apr 12, 2027

Study completion Apr 12, 2027

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
Pfizer
First posted
Sep 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety and effects of updated COVID-19 vaccines (called BNT162b2) in participants 5 Through 64 Years of Age with risk factors for Severe COVID-19, and Participants 65 Years of Age and Older. This study is seeking participants who: * are medically stable * have not had a recent COVID-19 infection or a recent COVID-19 vaccination * have not received certain routine vaccines recently * participants that are 5 through 64 years of age will need to have at least 1 medical condition that increase their risk of complications from COVID-19. Participants in Cohort 1 of this study will receive a single age-appropriate dose (30 mcg for participants aged ≥12 years; 10 mcg for participants aged 5-11 years) of BNT162b2 vaccine 1 which targets COVID-19 (2026/2027 recommended strain) injected in the upper arm. The study team and participants will know which injection they receive. Participants in Cohort 2 of this study will randomly receive 1 injection into their upper arm of either: BNT162b2 vaccine 1; BNT162b2 vaccine 2, or BNT162b2 vaccine 3 which targets COVID-19. The study team and participants will not know which injection they receive. Participants enrolled in Cohort 1 will be in the study for about 2 months and will have at least 3 scheduled visits. Participants enrolled in Cohort 2 will be in the study for about 6 months and will have at least 3 scheduled visits. Participants will record side effects and complete diaries following visit procedures. For Cohort 1 the study team will collect a nose swab and blood samples at 2 of the 3 visits. For Cohort 2 the study team will collect a nose swab and blood samples at all of the visits.

Conditions

  • COVID-19 Vaccines

Interventions

  • BNT162b2Biological

    BNT162b2 vaccine 1 (2026/2027 recommended strain)

  • BNT162b2Biological

    BNT162b2 vaccine 2

  • BNT162b2Biological

    BNT162b2 vaccine 3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants reporting local reactions or systemic eventsTime frame: For up to 7 days after vaccination
  2. Percentage of participants reporting adverse eventsTime frame: From vaccination through 1 month after vaccination
  3. Percentage of participants reporting serious adverse eventsTime frame: From vaccination up to 6 months
  4. Geometric Mean Fold Rise (GMFRs)Time frame: From baseline through 1 month after vaccination

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • C & R Research Servcies USA, Inc.

    Homestead, Florida

  • Indago Research & Health Center, Inc

    Miami Lakes, Florida

  • AGILE Clinical Research Trials, LLC

    Atlanta, Georgia

  • East-West Medical Research Institute

    Honolulu, Hawaii

  • Kentucky Pediatric /Adult Research

    Bardstown, Kentucky

  • Center for Immunization Research

    Baltimore, Maryland

  • Dayton Clinical Research

    Dayton, Ohio

  • Senders Pediatrics

    South Euclid, Ohio

  • DM Clinical Research

    Philadelphia, Pennsylvania

  • Cedar Health Research

    Dallas, Texas

  • Cedar Health Research

    Euless, Texas

  • DM Clinical Research-Cyfair

    Houston, Texas

  • DM Clinical Research

    Tomball, Texas

  • J. Lewis Research, Inc. / Foothill Family Clinic

    Salt Lake City, Utah

  • J. Lewis Research, Inc. / Foothill Family Clinic South

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.